Central vein sign and paramagnetic rim lesions in pediatric-onset multiple sclerosis: a systematic review and

Anna de Mauro1,2, Rosa Cortese1,2,3,4,5, Giulia Fadda6

  • 1Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.

Journal of Neurology
|August 22, 2026
PubMed
Abstract

Insights

Paramagnetic rim lesions (PRLs) are common in pediatric-onset multiple sclerosis (POMS), showing high diagnostic specificity. Central vein sign (CVS) is variable, and more pediatric-specific research is needed for accurate diagnosis.

Area of Science:

  • Neurology
  • Radiology
  • Pediatric Medicine

Background:

  • Susceptibility-based MRI biomarkers like paramagnetic rim lesions (PRLs) and central vein sign (CVS) are key in adult MS diagnosis.
  • Their diagnostic utility in pediatric-onset MS (POMS) requires further definition.

Purpose of the Study:

  • To systematically review and meta-analyze the prevalence and diagnostic value of PRLs and CVS in POMS.
  • To synthesize current evidence on these MRI biomarkers in pediatric MS patients.

Main Methods:

  • Conducted a PRISMA-compliant systematic review and random-effects meta-analysis.
  • Analyzed data from 11 studies on PRLs and CVS in POMS.
  • Assessed the proportion of patients with PRLs and CVS-positive lesions, and CVS threshold fulfillment.

Main Results:

  • Pooled prevalence of ≥1 PRL in POMS was 71.6% with low heterogeneity.
  • Pooled mean proportion of CVS-positive lesions was 57.9%, with 66.2% of patients meeting the 40%-CVS rule, showing substantial variability.
  • PRLs demonstrated high specificity for POMS; CVS was more prevalent in POMS than mimics, but data were limited.

Conclusions:

  • PRLs are frequent in POMS and may possess high diagnostic specificity.
  • CVS prevalence is variable in POMS, and current evidence for diagnostic accuracy in pediatrics is scarce.
  • Further pediatric-specific studies are essential to establish optimal diagnostic use of these MRI biomarkers in POMS.